Magenta Therapeutics, Inc.
THERAPEUTIC METHODS USING ANTIBODY DRUG CONJUGATES (ADCS)

Last updated:

Abstract:

The invention relates to dosing regimens for antibody drug conjugates, as well as methods of administering said dosing regimens to patients suffering from or at risk of various diseases and conditions such as autoimmune diseases, cancers, and Graft versus Host Disease (GvHD), among others, by administration of an antibody drug conjugate (ADC), capable of binding an antigen expressed by a hematopoietic cell, such as a hematopoietic stem cell, an immune cell or a cancer cell.

Status:
Application
Type:

Utility

Filling date:

4 Dec 2020

Issue date:

16 Sep 2021